Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE
Pharma Mar S.A.
Diffuse large B-cell lymphoma
1 trial -
Carbetocin Nasal Spray
Pharma Mar S.A.
Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)
1 trial -
Carbetocin Nasal Spray, Placebo to match carbetocin 11.4 mg/ml (2ml /vial)
Pharma Mar S.A.
Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)
1 trial -
Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat
Pharma Mar S.A.
Metastatic hormone-sensitive prostate cancer with high tumor load
1 trial -
Cemdisiran, Pozelimab
Pharma Mar S.A.
Paroxysmal nocturnal hemoglobinuria (PNH)
1 trial -
Cidofovir, Brincidofovir
Pharma Mar S.A.
Adenovirus viremia
1 trial -
Combipress 150 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 150 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία
Pharma Mar S.A.
Arterial Hypertension
1 trial -
Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.
Pharma Mar S.A.
Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.
1 trial -
DCC-3014, DCC-3014, Placebo to match DCC-3014
Pharma Mar S.A.
Tenosynovial Giant Cell Tumor
1 trial -
DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s
Pharma Mar S.A.
Relapsed Refractory Multiple Myeloma
1 trial -
DOXORUBICIN, Pralatrexate, PREDNISONE, Belinostat, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE
Pharma Mar S.A.
Peripheral T-Cell Lymphoma
1 trial -
DUOFAG, Chlorid sodný B. Braun 0,9 % infuzní roztok
Pharma Mar S.A.
Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
1 trial -
Depigoid Grass-Mix (1000 DPP/ml), Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, The placebo to be used in the clinical trial is the solvent used in the investigational medicinal products’ (IMPs) formulation. The resulting product is a suspension., Depigoid FORTE Grass-Mix (3000 DPP/ml)
Pharma Mar S.A.
Allergic rhinoconjunctivitis with or without controlled asthma
1 trial -
Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®
GlaxoSmithKline Biologicals S.A.
Multiple Myeloma
1 trial -
Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules
GlaxoSmithKline Biologicals S.A.
Relapsed/Refractory Multiple Myeloma
1 trial -
Dextrose / glucose 5% solution in water, Setrusumab
Pharma Mar S.A.
Osteogenesis imperfecta (OI)
1 trial -
Doxorubicin 2 mg/ml Solution for Injection., Fibromun
Philogen S.p.A.
Unresectable or metastatic soft tissue sarcoma
1 trial -
Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen
Pharma Mar S.A.
Atopic Dermatitis
1 trial -
Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.
Pharma Mar S.A.
Bipolar I Disorder
1 trial -
Epidyolex 100 mg/ml oral solution
Pharma Mar S.A.
Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome
1 trial -
Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).
Pharma Mar S.A.
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Etrasimod Arginine Blue
Pharma Mar S.A.
Ulcerative Colitis
1 trial -
Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue
Pharma Mar S.A.
Crohn's Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources